Want to see AVBP full AI Analyst Report?
AVBP Stock Chart & Stats
$29.64
$0.14(0.52%)
At close: 4:00 PM EST
$29.64
$0.14(0.52%)
Day’s Range― - ―
52-Week Range$16.10 - $35.83
Previous CloseN/A
Volume49.09K
Average Volume (3M)600.10K
Market Cap
$1.42B
Enterprise Value$713.75
Total Cash (Recent Filing)$326.38M
Total Debt (Recent Filing)$419.00K
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Aug 18, 2026EPS Estimate
-0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.53
Shares Outstanding46,574,930
10 Day Avg. Volume533,435
30 Day Avg. Volume600,103
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.52
Price to Sales (P/S)0.00
P/FCF Ratio-4.82
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$43.08Price Target Upside45.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-4.05
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage materially reduces near-term solvency and refinancing risk, giving management flexibility to fund clinical programs without immediate debt pressure. This durable capital structure supports multi-quarter R&D execution even if revenues remain absent.
Strengthened Asset BaseA materially larger asset base increases the company's liquidity cushion and optionality to support ongoing trials, partnerships, or licensing. This structural improvement lengthens runway and enhances credibility with partners and capital providers over months.
Governance ContinuityRe-election of directors and auditor continuity reduces execution risk from leadership turnover and preserves consistent financial oversight. Stable governance supports long-term strategic planning, regulatory readiness, and investor confidence during multi-year clinical development.
Bears Say
Pre-Revenue With Large LossesBeing pre-revenue with widening net losses means value depends entirely on future clinical and commercialization success. Persistent negative earnings erode equity over time and create structural execution risk until products generate sustainable sales.
Sustained High Cash BurnLarge, recurring negative operating and free cash flows create an ongoing need for external financing. This structurally increases dilution risk, forces capital raising timing to dictate strategy, and limits the firm's ability to self-fund expanded trials or commercialization.
Dependence On Equity FinancingFormalizing an ATM for up to $250M signals structural reliance on public equity to fund operations. While it provides flexibility, it also implies likely dilution, and long-term strategy may be constrained by capital market conditions and shareholder dilution concerns.
ArriVent BioPharma, Inc. News
AVBP FAQ
What was ArriVent BioPharma, Inc.’s price range in the past 12 months?
ArriVent BioPharma, Inc. lowest stock price was $16.10 and its highest was $35.83 in the past 12 months.
What is ArriVent BioPharma, Inc.’s market cap?
ArriVent BioPharma, Inc.’s market cap is $1.42B.
When is ArriVent BioPharma, Inc.’s upcoming earnings report date?
ArriVent BioPharma, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 25 days.
How were ArriVent BioPharma, Inc.’s earnings last quarter?
ArriVent BioPharma, Inc. released its earnings results on May 11, 2026. The company reported -$0.96 earnings per share for the quarter, missing the consensus estimate of -$0.895 by -$0.065.
Is ArriVent BioPharma, Inc. overvalued?
According to Wall Street analysts ArriVent BioPharma, Inc.’s price is currently Undervalued.
Does ArriVent BioPharma, Inc. pay dividends?
ArriVent BioPharma, Inc. does not currently pay dividends.
What is ArriVent BioPharma, Inc.’s EPS estimate?
ArriVent BioPharma, Inc.’s EPS estimate is -0.99.
How many shares outstanding does ArriVent BioPharma, Inc. have?
ArriVent BioPharma, Inc. has 46,574,930 shares outstanding.
What happened to ArriVent BioPharma, Inc.’s price movement after its last earnings report?
ArriVent BioPharma, Inc. reported an EPS of -$0.96 in its last earnings report, missing expectations of -$0.895. Following the earnings report the stock price went down -0.172%.
Which hedge fund is a major shareholder of ArriVent BioPharma, Inc.?
Currently, no hedge funds are holding shares in AVBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ArriVent BioPharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.08 (45.35% Upside)
$43.08 (45.35% Upside)
Blogger Sentiment
Bullish
AVBP Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 35.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.08%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
62.09%
Trailing 12-Months
Company Description
ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
AVBP Stock 12 Month Forecast
Average Price Target
$43.08
▲(45.35% Upside)
Technical Analysis
uniQure
―
Iovance Biotherapeutics
―
Relay Therapeutics
―
Inventiva
―
Taysha Gene Therapies
―
Ownership Overview
9.57% Insiders
12.10% Mutual Funds
0.27% Other Institutional Investors
65.94% Public Companies and
Individual Investors